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Since the Expanded Programme on Immunisation (EPI) was 
introduced in 1974, immunisation has played a significant role in 
reducing childhood morbidity and mortality caused by vaccine 
preventable diseases (VPDs) globally.[1]
To advance and maximise the public health benefits of 
immunisation at national level, the 2011 - 2020 Global Vaccine 
Action Plan (GVAP) outlined its first strategy as getting ‘all countries 
commit to immunisation as a priority’.[2] Countries’ commitment 
should go hand in hand with ownership, although this is not always 
the case. Closely linked with the country’s immunisation ownership 
is the presence of a national immunisation technical advisory group 
(NITAG).[2] NITAG is a multidisciplinary group of national experts 
who independently advise national immunisation programmes 
(NIPs) on matters related to vaccines and immunisation.[3] The advice 
provided by NITAGs must be evidence based and locally relevant. 
Therefore, vaccine and immunisation research is critical in building 
the evidence base that NITAGs use to advise NIPs. 
As with the 2011 - 2020 GVAP, the core principle of the World 
Health Organization (WHO) Immunisation Agenda 2030 is to be 
people focused, country owned, partnership based and data enabled. 
Considering this, there is a need for immunisation data that highlight 
critical gaps in vaccine research. Such data could contribute to 
advancing the research agenda to build an evidence base and support 
NIPs.[4] It is also worth noting that the emergence of the COVID-19 
pandemic further emphasises the need for appropriate evidence 
generation to inform national immunisation practices and policies 
during crises.
Globally, the immunisation landscape has significantly evolved 
since the establishment of EPI in 1974. As EPI developed and 
expanded into low- and middle-income countries (LMICs), more 
information was required to inform decision and implement policies.
A previous study investigating vaccine research in Africa between 
1970 and 2010, reported an uneven distribution of research outputs 
across countries. Of the research included in the study, 6 countries 
accounted for over half of the research outputs. The authors identified 
the need for development of research capacity in LMICs in general.[5] 
Mashingaidze et al.’s[5] study was later updated for 2011 - 2017. The 
findings from the updated study[6] alluded to vastly increased research 
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Background. Research in human vaccines and immunisation plays a crucial role in shaping national, regional and global health policies aimed 
at controlling vaccine preventable diseases (VPDs). To our knowledge, the landscape of human vaccine and immunisation research in South 
Africa (SA) is not well characterised. 
Objectives. To characterise research in human vaccines and immunisation in SA. 
Methods. We conducted a bibliometric study. Seven electronic databases (PubMed; Scopus; Web of Science; Cochrane; CINAHL; Africa-Wide 
Information; and MEDLINE (via EBSCOhost)) were searched for eligible studies published in English between 1 January 2007 and 
31 March 2020. Selected primary studies needed to be on human vaccine and immunisation research conducted in SA. All types of reviews 
were excluded. For the included studies, outcomes of interest included publication journals, publication trends, types of studies and VPDs, 
targeted populations, as well as author affiliations.
Results. A total of 9 212 studies was retrieved. After screening for eligibility, 366 studies met the inclusion criteria. The key findings were as 
follows: (i) a total of 54 (14.8 %) articles on human vaccine and immunisation research in SA appeared in local journals, while 312 (85.2%) were 
in non-SA (international) journals; (ii) the number of publications on human vaccine and immunisation research in SA increased from 13 in 
2007 to 47 in 2015; (iii) there were 189 (51.7%) operational studies and 177 (48.3%) clinical studies, with 88 (49.7%) of the latter being clinical 
trials; (iv) human vaccine and immunisation research in SA is conducted across all age groups, with a focus on children; and (v) authors of 
the identified research outputs and those mostly represented were from the universities of Cape Town and the Witwatersrand, Johannesburg.
Conclusions. The landscape of human vaccine and immunisation research in SA is growing and adapting to the emerging trends in vaccinology, 
with a focus on the duo epidemic of HIV and TB, as well as Expanded Programme on Immunisation (EPI)-related vaccinations. This research 
contributes to locally relevant evidence that can be used to inform future vaccine and EPI-related research. 
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outputs driven by the burden of disease on the continent and a need 
to address the lack of finance and policy-related research that had also 
been present in the previous study. Vaccine and immunisation research 
from SA featured prominently in Machingaidze et al.’s[5] study and 
the updated study.[6] We were therefore interested in a more detailed 
characterisation of SA human vaccine and immunisation research.
The immunisation landscape has significantly evolved since the 
establishment of EPI in SA (EPI-SA). This is evidenced by the 
evolution of the vaccination schedule and the establishment of the 
National Advisory Group on Immunisation (NAGI) in 1993 to 
advise the National Department of Health (DoH) on issues related 
to vaccination.[7] For example, the first vaccines introduced into EPI-SA 
were for diphtheria, tetanus and pertussis (DTP), measles, polio and 
bacille Calmette-Guérin (BCG) vaccines. As EPI-SA evolved, new 
vaccines were introduced, such as the hepatitis B vaccine in 1995 
and Haemophilus influenzae type B vaccine in 1999. Since then, 
pneumococcal vaccine (PCV) and rotavirus vaccine were introduced 
in 2009, while human papillomavirus (HPV) vaccine was introduced 
in 2014.[1]
NAGI plays an instrumental role in the introduction of several 
new vaccines to the NIP but also to related matters, such as 
expanding immunisation services to all age groups and vaccination 
during the COVID-19 crisis.[1,7] Among other successes of EPI-SA 
are elimination of neonatal tetanus in 2002 and the country being 
declared polio free in 2006.[8] The evolution of SA’s immunisation 
landscape brings with it challenges that require use of locally available 
evidence to strengthen the NIP. A key area of SA’s NIP that requires 
strengthening is improvement of vaccination coverage. 
High-quality, relevant and timely national evidence is needed to 
inform immunisation practices and policies aimed at effective control 
of VPDs. The evidence needed is generated from diverse initiatives 
that include research. Research in vaccines and immunisation plays 
an important role in shaping immunisation policies at national level. 
It is therefore important to take stock of the research landscape 
involving vaccines and immunisation in SA.
Objectives
The objective of this study was to characterise human vaccine and 
immunisation research in SA by means of: (i) the most published 
journals; (ii) trends in the number of studies published annually; 
(iii) trends in the type of studies published; (iv) the most researched 
diseases; and (v) the affiliation of the first authors of the relevant studies.
Methods
Search strategy
We conducted a bibliometric study. Seven electronic databases 
(PubMed; Scopus; Web of Science; Cochrane; CINAHL; Africa-Wide 
Information; and MEDLINE (via EBSCOhost)) were searched for 
eligible studies published in English between 1 Jan uary 2007 and 
31 March 2020. We chose 2007 - 2020, as the period was character-
ised by rapid developments in vaccinology and the introduction of 
new vaccines into the NIP. A combination of medical subheadings 
(MeSH) and free search terms for vaccines, vaccination, immunisa-
tion and SA were used. The full search strategy that was used in 
PubMed is shown in Table 1. 
Study selection
Studies were included if they: (i) were conducted in humans; (ii) were 
conducted in SA; and (iii) focused on vaccines, immunisation 
programmes, policies or epidemiology of VPDs targeted by 
traditional or new vaccines. Studies reporting the epidemiology of 
VPDs without any reference to a specific vaccine were excluded, 
while only primary studies were included. All types of reviews were 
excluded.
Following the search, all retrieved articles were uploaded into 
EndNote V9 (Clarivate Analytics, USA), where duplicates were 
removed. The articles were then exported from EndNote to 
Rayyan (Qatar Computing Research Institute, Qatar), where the 
titles and abstracts were screened.[9] The articles were screened 
by one reviewer (MIM) and verified by a second reviewer (ECH). 
Disparities that arose during the review process were resolved by 
discussion and consensus by inviting one of the co-authors to serve 
as a third reviewer.
Data extraction and analyses
Data from included articles were extracted by one reviewer (MIM) 
using a predesigned data extraction form, and verified by a second 
reviewer (ECH). Extracted data consisted of the study period, type of 
study (clinical or operational), class of study, targeted vaccine, disease 
and population, as well as the affiliation of the first author, i.e. listed 
as ‘1’. Information regarding journal impact factor (JIF) was extracted. 
Extracted data were then imported into STATA version 14 (StataCorp., 
USA) for analysis. Results were presented as proportions.
The number of publications per journal was tabulated. Journals 
were ranked based on the number of published studies. In the event 
of a tie, journals were ranked in descending order using their latest JIF 
retrieved from Clarivate Analytics (Clarivate, USA). Included studies 
were stratified by affiliations (academic institutions) of the authors. 
Results
Our search yielded 9 212 articles: 1 216 from PubMed; 416 from 
Cochrane; 4 310 from EBSCOhost; 1 825 from Scopus; and 1 445 
from Web of Science. Of these 9 212 articles, 24 were identified 
through alerts from the relevant databases.
Using EndNote and Rayyan, 3 631 duplicates were removed, leaving 
5 581 studies for screening. Based on titles and abstracts, 638 articles 
Table 1. A summary of the search query
#1 Vaccine (MeSH) OR Immuni* (MeSH) OR Vaccination (MeSH) OR ‘Immuni* Schedule’ OR ‘Immuni* Program’ OR 
‘Expanded Programme on Immuni*’ OR EPI OR Vaccinate OR ‘Mass Vaccination’ OR ‘Routine Vaccination’ OR ‘School 
Based Vaccination’ OR ‘Outreach Vaccination’ OR ‘Supplementary Vaccination’ OR ‘Catch up Vaccination’ OR ‘Vaccine 
Trial’ OR ‘Vaccine Acceptance’ OR ‘Vaccine Hesitancy’ OR ‘Vaccine Induced Immunity’ OR Immunogenicity OR ‘Immune 
Response’ OR ‘Vaccination Coverage’ OR ‘Vaccine Knowledge’ 
#2 ‘Republic of South Africa’ OR ‘South Africa’ 
#3 #1 AND #2
Filters Publication year: 1 January 2007 - 31 December 2019; Language: English; Population: Human; Geographical focus:  
South Africa
Search date 21 June 2019 updated via alerts till 31 March 2020
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were retained for full-text assessment. Of 
these, 366 met the inclusion criteria. The 
literature screening and selection process 
are shown in Fig. 1, using the Preferred 
Reporting Items for Systematic Reviews and 
Meta-Analyses (PRISMA) statement.[10]
Characteristics of included studies
The 366 included studies were published 
in 101 peer-reviewed journals. The highest 
number of studies was published in Vaccine 
(n=75; 20.5%), followed by SAMJ (n=30; 
8.2%) and PLoS ONE (n=24; 6.6%). Of 
the 366 studies included, 54 (14.8%) were 
published in 10 local (SA) journals and 312 
(85.2%) in international (non-SA) journals. 
Table 2 shows the top 10 journals where 
the included studies were published. The 
corresponding JIF is indicated.
Trends in the number of published 
studies, 2007 - 2019
In 2007, only 13 vaccine and immunisation 
research articles were published compared 
with 47 studies in 2015. A steady increase 
in the number of published studies was 
observed between 2009 and 2013. We 
unexpectedly observed a steady decline in 
the number of published studies from 2015 
(n=47) to 2017 (n=27), followed by a sudden 
increase to 37 in 2019 (Fig. 2). In the first 
quarter of 2020, we identified 5 published 
studies (data not shown on the graph). 
Trends in the types of human vaccine 
and immunisation studies in SA, 
2007 - 2019
Trends in types of studies over time
From 2007 to 2009, we observed several 
knowledge, attitude and practice (KAP) 
(n=7; 17.1%), burden of disease (BOD) (n=6; 
14.6%) and advocacy (n=8; 19.5%) studies. 
In 2010, the largest number of KAP (n=8; 
44.4%) and vaccine-coverage studies (n=6; 
33.33%) were published in a single year. 
Additionally, we observed an increase in 
clinical trials (n=6; 33.33%). The trend in 
clinical trials remained steady from 2010 to 
2019 (n=6 - 8), except in 2014 (n=14; 41.1%) 
and 2017 (n=11; 40.7%), during which a 
large proportion of studies was published. 
Advocacy studies occurred most frequently 
during 2015 (n=12; 25.5%) and 2018 (n=8; 
25%). The number of immunology studies 
remained between 1 and 3 annually, except 
for 2013 (n=4; 10.5%), 2015 (n=5; 10.6%) 
and 2016 (n=4; 12.1%) (Fig. 3).
Classification of included studies
Type
Operational studies (n=189; 51.7%) were pub-
lished relatively more often than clinical studies 
(n=177; 48,3%). Among the operational studies, 
most were KAP studies (n=57; 30.1%), followed 
by studies on advocacy (n=52; 27.5%) and 
vaccine coverage (n=23; 12.2%). For clinical 
studies, the largest outputs were clinical trials 
(n=88; 49.7%) and BOD studies (n=56; 31.6%) 
(Table 3). 
Disease
A total of 318 (86.9%) of the studies focused 
on a single disease. Studies focusing on HIV 
made the largest individual contribution to 
the relevant research outputs (n=75; 23.6%), 
with HPV (n=63; 19.8%) and tuberculosis 
(TB) (n=61; 16.7%) comprising the second 
and third largest contributions, respectively. 
Forty-eight studies involved multiple VPDs 
covered in EPI-SA (Table 4). 
Study population 
One hundred and twenty-two (33.3%) studies 
focused on childhood-only immunisation, 
followed by adult-only immunisation (n=88; 
24%). Studies involving adolescent-only 
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Fig. 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram.
Table 2. Top 10 journals where the included studies were published, N=182
Journal Journal impact factor, 2018 Studies, n (%)
Vaccine 3.269 75 (20.5)
South African Medical Journal (SAMJ) 1.5 30 (8.2)
PLoS ONE 2.776 24 (6.6)
Paediatric Infectious Diseases Journal 2.456 12 (3.3)
Journal of Infectious Diseases 5.045 8 (2.2)
Human Vaccines and Immunotherapeutics 2.592 8 (2.2)
Clinical Infectious Diseases 9.055 7 (1.9)
New England Journal of Medicine (NEJM) 70.670 6 (1.6)
Expert Review of Vaccines 4.551 6 (1.6)
International Journal of Infectious Diseases 3.538 6 (1.6)
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immunisation accounted for just 26 (7.1%) 
of all studies reviewed. The remaining 130 
(35.5%) studies involved multiple age groups 
(Fig. 4).
Affiliation of first authors of vaccine 
and immunisation studies
Of the 366 studies, the first authors of 
256 studies were affiliated with 28 SA 
institutions. Of the 256 SA-affiliated 
studies, 200 were affiliated with 10 uni-
ver sities; 9 with 7 hospitals; 44 with 
10 private institutions; and 3 with SA 
independent science writers. Two studies 
were affiliated with 2 universities from 
Malawi and Senegal. The remaining 
108 studies were affiliated with 60 non-
African institutions, of which 67 studies 
were affiliated with 35 non-African 
universities, 1 study was affiliated with a 
US hospital and 40 studies were affiliated 
with 24 private institutions. 
Discussion 
We successfully identified and profiled 
research outputs on human vaccines and 
immunisation in SA between 2007 and 2019. 
Our key findings were as follows: (i) research 
outputs on human vaccines and immunisation 
are published in both SA (local) journals and 
non-SA (international) journals; (ii) there was 
a steady increase in the number of publications 
on human vaccine and immunisation research 
outputs in SA over the period under review; 
(iii) clinical trials, BOD and KAP studies 
dominated the published research outputs 
during the study period; (iv) human vaccine 
and immunisation research outputs in SA 
are conducted across all age groups, with 
more focus on children; and (v) the most 
represented authors of the identified research 
outputs were from the universities of Cape 
Town and the Witwatersrand, Johannesburg.
Journal altmetrics are routinely consi-
dered by researchers when choosing a 
journal in which to publish.[11] Other reasons 
for choosing to publish in certain journals 
are the journal’s rate of acceptance and 
interest in the study. This is important, 
because journal acceptance rates are widely 
recognised to be limited. Therefore, authors 
often require multiple submissions prior to 
being published. Given a choice, in addition 
to the scope, most researchers would opt 
to publish their research in a journal with 
a high JIF, such as NEJM.[12] Of note is that 
only 54 (14.8%) studies were published in 
SA journals and 310 (85.2%) in international 
journals. However, of the top 10 journals 
where the research outputs of interest were 
published, SAMJ (local journal) had the 
lowest JIF (1.5) and yet, the journal ranked 
second. This is an encouraging finding, 
given that local journals are a useful source 
of local evidence. 
Impressively, a steady increase in research 
outputs was observed between 2007 and 
2015. This period coincided with the 
introduction of new vaccines by EPI-SA, 
such as those against rotavirus, pneumococcal 
disease, pertussis and HPV.[1] When we 
assessed the research outputs by topics, HPV, 
pneumococcal disease and rotavirus were 
among the top 6. This may suggest that the 
introduction of new vaccines could have 
enhanced research on topics related to these 
vaccines. There was an unexpected sharp 
decline in publication outputs in 2016 and 
2017, despite an increase in gross expenditure 
on research and development in SA.[13] Our 
speculation in this regard is that absence 
of new vaccine introduction during 2015 - 
2019 may partly explain the decline. This 

















































Fig. 2. Trend in the number of published vaccine and immunisation research studies in South Africa 
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Fig 3. Trend in the types of human vaccine and immunisation studies in South Africa from 2007 to 
2019. (AEFI = adverse events following immunisation; BOD = burden of disease; KAP = knowledge, 
attitude and practice; EPI-SA = Expanded Programme on Immunisation in South Africa.) 
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which were introduced into EPI-SA in 2014. During this period, we 
observed the following trends: HPV studies were mostly published 
between 2013 and 2015 (n=27), with a decrease to 3 studies published 
between 2016 and 2017, and an increase to 17 studies published 
between 2018 and 2019. The trend in rotavirus-related publications 
follows a similar pattern, with 11 studies published between 2012 and 
2015 and 4 studies published between 2016 and 2019.
Another factor worth noting is the high number of advocacy 
studies published in 2015 (n=11), with a subsequent decrease in the 
following years, ranging from a low of 2 in 2017 to a high of 7 in 2018. 
We posit that this was potentially instrumental towards the increase 
in gross expenditure on research. Interestingly, we observed a sharp 
increase in publication outputs between 2018 and 2019. We attribute 
the increase to the need for improving awareness and knowledge on 
immunisation as a result of recurrent outbreaks of VPDs, such as 
measles.[14] A large proportion of research outputs published in 2018 
and 2019 was focused on KAP and advocacy concerning vaccines. 
For example, 19 of the 32 studies published in 2018 were operational 
studies, of which 12 focused on KAP and vaccine advocacy in SA. 
Published studies on BOD and KAP featured prominently, which is a 
positive finding, given that both types of studies are critical in guiding 
immunisation practices and policies in SA. KAP studies were mainly 
related to HIV vaccine trials and HPV vaccination programmes. 
Studies included also focused on catch-up vaccinations related to 
HPV to prevent cervical cancer in adult women, and on measles 
to monitor the effect of mass immunisation activities following the 
measles outbreak of 2009 - 2011. Admirably, the types of studies most 
published appeared to align with the DoH’s strategic plan for 2015 - 
2020, which emphasises the need to promote health and prevent and 
reduce the disproportionate burden of disease, especially the HIV 
and TB epidemic.[15] 
Regarding the types of research that were most published, clinical 
trials topped the list. SA is endemic for TB and HIV, the duo of 
epidemics that puts considerable pressure on the country’s health 
system.[16] Given that new vaccines against TB and HIV epidemics 
are a public health priority, the country is at the forefront of guiding 
the development and testing of candidate vaccines against these 
diseases.[17] Also worth noting is that the identified research outputs 
were conducted in all population groups, i.e. children, adolescents 
and adults. This is an encouraging finding as life-course vaccination 
(vaccinating all age groups) has been identified as a key strategy to 
optimise the benefits of vaccines.[18] 
Affiliations of authors give an indication of institutions at the 
forefront of vaccine and immunisation research in SA. First authors 
of most of the identified research outputs were affiliated with the 
universities of Cape Town and the Witwatersrand. This is not a 
surprising observation, as these are the top two ranked institutions 
in the country by the Times Higher Education world university 
rankings.[19] 
Furthermore, the presence of established vaccine research units 
in specific organisations or universities contributes towards research 
outputs. It is therefore no surprise that institutions such as the 
Table 3. Classification of the types of vaccine and 
immunisation studies, N=366
Type of study Studies, n (%)
Clinical 177 (48.3)
Clinical trials (phase 1 - 4) 88 (49.7)




Knowledge attitude and practice 57 (30,1)
Advocacy 56 (29.6)




EPI-SA service integration 4 (2.1)
Service delivery 2 (1.05)
Management 2 (1.05)
AEFI = adverse events following immunisation; EPI-SA = Expanded Programme on 
Immunisation in South Africa.
Table 4. Published studies reported by type of the disease, 
N=366
Disease Studies, n (%)
HIV 75 (23.6)
Human papillomavirus 63 (19.8)
Tuberculosis 61 (16.7)
Multiple VPDs with EPI-SA 48 (13.1)
Influenza-related illness 30 (8.2)
Pneumococcal disease 30 (8.2)
Rotavirus 17 (4.6)
Hepatitis B virus 14 (3.8)
Measles 7 (1.9)
Streptococcal disease 6 (1.6)
Polio 4 (1.1)
Neisserria meningitidis 3 (0.8)
Haemophillus influenza type B 2 (0.6)
Rubella 2 (0.6)
Hepatitis A virus 2 (0.6)
Malaria 1 (0.3)
Pertussis 1 (0.3)
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Fig. 4. Distribution of South African vaccine and immunisation research per 
targeted age group.
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universities of Cape Town and the Witwatersrand were observed to 
be at the forefront of vaccine-related research.
The affiliations of co-authors could also suggest the scope of 
research collaborations in the field of vaccine and immunisation 
research, although this was not explored as part of the current study. 
Study limitations
This bibliometric study has some limitations that are worth noting 
in the context of our findings. Systematic reviews, meta-analyses 
and guidelines were not considered for inclusion, as we focused on 
primary studies. It is generally recognised that evidence syntheses 
and guidelines are essential in shaping immunisation practices 
and policies. Grey literature and non-English articles were also not 
included, which may have resulted in the exclusion of potentially 
relevant data. 
To further improve the publication of research in local journals, 
we propose that researchers should be incentivised and encouraged. 
For example, incentivisation could be done through weighting of 
researchers’ contributions to the local research publication when 
applying for local funding, as well as academic promotions.
Conclusions
Our findings summarise the types and trends of human vaccine and 
immunisation research in SA. To our knowledge, this summary has 
been lacking, except for a literature review conducted as part of a 
larger study.[20] Our study improved on this by restricting included 
studies to human vaccine-related work and using a systematic review 
methodology, thus producing evidence that more accurately reflects 
the trends and types of human vaccine and immunisation research in 
SA. Our findings show a similar profile of vaccine and immunisation 
research reported previously at a regional level.[5,6] These findings 
should be used to inform and support immunisation policies and 
practices locally by highlighting gaps in key areas of immunisation 
research that need to be better addressed to ensure that immunisation 
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